CABA - CIK 0001759138
The table below shows Cabaletta Bio, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $37.35M | $39.82M | $37.64M | $29.02M | $26.29M | $23.43M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.94M |
| $6.76M |
| $8.27M |
| $8.12M |
| $6.76M |
| $6.85M |
| Operating income | -$44.30M | -$46.59M | -$45.91M | -$37.14M | -$33.05M | -$30.28M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$43.52M | -$44.87M | -$45.13M | -$35.94M | -$30.63M | -$27.60M |
| EPS (diluted) | -$0.39 | -$0.44 | -$0.73 | -$0.71 | -$0.62 | -$0.56 |